Pharmacodynamics of rituximab on B cells in paediatric post-HSCT patients with EBV Poster Pharmacodynamics of rituximab on B cells in paediatric post-HSCT patients with EBV CertaraJune 24, 2019
Optimize Immuno-oncology Drug Discovery and Development Using QSP White Paper Optimize Immuno-oncology Drug Discovery and Development Using QSP A Quantitative Systems Pharmacology (QSP) approach for developing combination immune-oncology therapies can be used to…CertaraJune 19, 2019
Pirana Modeling Workbench Brochure Pirana Modeling Workbench Pirana is a flexible and extendible modeling workbench with an intuitive graphical user interface for…CertaraMay 28, 2019
Population Pharmacokinetic Analysis of DS-8201a, A HER2-Targeting Antibody-Drug Conjugate, in Patients with HER2-Positive Breast Cancer or Other Solid Tumors Poster Population Pharmacokinetic Analysis of DS-8201a, A HER2-Targeting Antibody-Drug Conjugate, in Patients with HER2-Positive Breast Cancer or Other Solid Tumors CertaraMay 2, 2019
Simulating the Impact of the Interplay Between CYP2C19 Polymorphisms and Ethnicity on Response to Clopidogrel, Using PBPK-PD Models Poster Simulating the Impact of the Interplay Between CYP2C19 Polymorphisms and Ethnicity on Response to Clopidogrel, Using PBPK-PD Models CertaraApril 22, 2019
Exposure-Response Analyses to Support Dose Justification of DS-8201A, A HER2-Targeting Antibody-Drug Conjugate, in HER2-Positive Breast Cancer Patients Poster Exposure-Response Analyses to Support Dose Justification of DS-8201A, A HER2-Targeting Antibody-Drug Conjugate, in HER2-Positive Breast Cancer Patients CertaraApril 22, 2019
Relationship of Ivosidenib Plasma Concentration to Heart Rate-Corrected QT Interval in Patients with IDH1-Mutant Advanced Hematologic Malignancies Poster Relationship of Ivosidenib Plasma Concentration to Heart Rate-Corrected QT Interval in Patients with IDH1-Mutant Advanced Hematologic Malignancies CertaraApril 22, 2019
Validation of the Pharmacokinetic/Pharmacodynamic Model Used for Dose Selection of Andexanet Alfa for Reversal of Anticoagulation Poster Validation of the Pharmacokinetic/Pharmacodynamic Model Used for Dose Selection of Andexanet Alfa for Reversal of Anticoagulation CertaraApril 22, 2019
How to Perform IVIVC for Extremely Long Acting Drugs On-Demand Webinar How to Perform IVIVC for Extremely Long Acting Drugs Watch this webinar to learn how to use in vitro and in vivo models to…CertaraFebruary 22, 2019
Automated Average Bioequivalence Analysis with Additional Metrics and Statistics to Meet the FDA Guidance on Methylphenidate Hydrochloride Using Phoenix WinNonlin Poster Automated Average Bioequivalence Analysis with Additional Metrics and Statistics to Meet the FDA Guidance on Methylphenidate Hydrochloride Using Phoenix WinNonlin CertaraNovember 4, 2018